A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and monitoring board indicated that the regimen being studied is superior to current care, and more patient data was extremely unlikely to change the trial’s outcome. Read about it here.
top of page
Recent Posts
See AllJohn Green’s new book Everything is Tuberculosis is scheduled to be published in Spring 2025. The novel laces the experiences of Henry, a...
110
The SIILTIBCY test is now available worldwide through the STOP TB GDF for $1.50 per dose. This novel testing option provides an...
80
The WHO has released the 2024 Global Tuberculosis Report and it places TB as the leading infectious disease killer, surpassing COVID-19....
150
bottom of page
Comments